The dual roles of the CCL2/CCR2 axis in cancer development can lead to opposite results, as patients with higher CCL2 or CCR2 expression had significantly better OS in NSCLC [153] but shorter OS and progression-free survival in diffuse large B cell lymphoma (DLBCL) [160], although evidence about the roles of CCL2/CCR2 in DLBCL is limited. The gene discussed is CCL2; the disease is cancer.